CRISPR Skriuwt de Genêskunde Flugger Om as Tafersjochhâlders Byhâlde Kinne
June 5, 2026 · Frisian News
Gene-editing companies deploy CRISPR treatments in clinics and overseas markets while regulatory agencies struggle to keep pace with the science. The gap between innovation and approval creates both opportunity and risk for patients.
FryskEditas Medicine melde yn april dat syn CRISPR-behanneling foar in seldsume eachkwaal it each werombrocht hie by trettjin pasjinten dy't klinysk blyn wiene. It bedriuw stiet oan op FDA-goedkarring yn 2027. Mar tafersjochhâlders hawwe sûnt 2023 mar twa CRISPR-terapyen wrâldwiid goedkard, wylst tsientallen oaren yn klinyske proeven of al yn minder regulearre lannen aktyf binne. It tempoferskil is net tafallich. It wjerspegelet hoe fluch genteknology beweecht yn fergeliking mei hoe't burokrasyën feiligens beoardielje.
Sina en Yndia binne flugger gien as it Westen. Sineeske klinieken fiere CRISPR-proeven út dy't yn de Feriene Steaten of Europa jierren lang ûndersyk fan tafersjochhâlders tsjinkomme soene. Guon proeven operearje yn griize sônes en biede eksperimintele behannellingen oan rike pasjinten foardat gegevens feiligens of wurksamheid bewize. Dit makket in echt probleem: rike minsken krije tagong ta net bewiisde terapyen, wylst gewoane boargers yn regulearre lannen wachtsje moatte. De struktuer fan prikkels befoarderet fluchheid boppe soarchfâldens, en bedriuwen witte dat tafersjochhâlders behannellingen dy't al tûzenen pasjinten yn it bûtenlân holpen hawwe net ôfwize kinne.
De FDA en it Europeesk Genêsmiddelenburo wrakselje mei in fundamentele fraach dy't hja net oplost hawwe. Hoe beoardielest in ienmalige genetyske bewurking dy't de makkers sizze it hiele libben fan in pasjint te wurkjen? Tradisjonele medisijnproeven rinne jierren. Genterapyproeven kinne dat net, om't de behanneling ienmalich plakfynt. Tafersjochhâlders freegje om langtermyngegevens dy't noch net bestean. Editas en konkurrinten stelle dat dizze standert ferâldere is. Se wize op echte pasjinten mei echte sykten dy't hjoed profitearje kinne.
Jild streamt nei wa't it fluchst beweecht. Editas, CRISPR Therapeutics, Intellia en Beam Therapeutics hawwe miljarden ophelle yn risikokapitaal en iepenbiere merken. Dizze bedriuwen kinne proeven yn meardere lannen tagelyk útfiere. Se hiere eardere tafersjochhâlders yn as adviseurs. Se dringe oan op fluggerder goedkardingspaden. Tradisjonele farmaseutyske bedriuwen, bûn oan âldere goedkarringstelsels, kinne net konkurearje. Dit feroaret wat behannele wurdt: CRISPR-bedriuwen rjochtsje harsels op seldsume genetyske sykten mei lytse pasjintpopulaasjes, dêr't goedkarring flugger komt. Folle foarkommende sykten lykas diabetes of hartsykte freegje om gruttere proeven en wachtsje langer, as hja alhielendal ûndersocht wurde.
De echte fraach dy't gjinien beantwurdzje wol: wa bepaalt oft fluchheid it risiko wurdich is? Tafersjochhâlders nimme oan dat pasjinten wachtsje wolle op perfekte gegevens. Pasjinten mei stjerrend each of in degenerative sykte geane derfan út dat hja it no probearje wolle. No bepale jild en geografy. Dat is gjin systeem. It is gaos klaaid as ynnovaasje.
Editas Medicine reported in April that its CRISPR treatment for a rare eye disorder had restored sight in thirteen patients who were clinically blind. The company is pushing for FDA approval in 2027. But regulators have approved exactly two CRISPR therapies worldwide since 2023, while dozens more are in clinical trials or already operating in less regulated countries. The pace mismatch is not accidental. It reflects how quickly gene-editing technology moves compared to how bureaucracies assess safety.
China and India have moved faster than the West. Chinese clinics run CRISPR trials that would face years of regulatory review in the United States or Europe. Some trials operate in gray zones, offering experimental treatments to wealthy patients before data proves safety or efficacy. This creates a real problem: wealthy people get access to unproven therapies while ordinary citizens in regulated countries must wait. The incentive structure favors speed over caution, and companies know regulators cannot reject treatments that have already helped thousands of patients abroad.
The FDA and European Medicines Agency struggle with a fundamental question they have not solved. How do you assess a one-time genetic edit that its makers claim will work for a patient's entire life? Traditional drug trials run for years. Gene therapy trials cannot, because the treatment happens once. Regulators ask for long-term data that does not yet exist. Editas and competitors argue this standard is outdated. They point to real patients with real diseases who could benefit today.
Money flows to whoever moves fastest. Editas, CRISPR Therapeutics, Intellia, and Beam Therapeutics have raised billions in venture capital and public markets. These companies can afford to run trials in multiple countries at once. They hire regulators' own former staff as consultants. They lobby for faster pathways. Traditional pharmaceutical companies, bound by older approval rules, cannot compete. This reshapes what gets treated: CRISPR companies focus on rare genetic diseases with small patient populations, where approval comes faster. Common diseases like diabetes or heart disease require bigger trials and wait longer, if they get pursued at all.
The real question nobody wants to answer: who decides if speed is worth the risk? Regulators assume patients want to wait for perfect data. Patients with dying vision or degenerative disease assume they want to try something now. Right now, money and geography decide. That is not a system. It is chaos dressed up as innovation.
Published June 5, 2026 · Frisian News · Ljouwert, Fryslân